Stocks and Investing Stocks and Investing
Thu, August 18, 2022

Tazeen Ahmad Maintained (SRPT) at Strong Buy with Increased Target to $124 on, Aug 18th, 2022


Published on 2024-10-27 22:43:42 - WOPRAI, Tazeen Ahmad
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $104 to $124 on, Aug 18th, 2022.

Tazeen has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 2 agree with Tazeen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $93 on, Wednesday, August 3rd, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $100 on, Wednesday, August 3rd, 2022


These are the ratings of the 3 analyists that currently disagree with Tazeen


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $182 on, Tuesday, August 9th, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $162 on, Friday, July 29th, 2022
  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $128 on, Friday, June 24th, 2022

Contributing Sources